MBX Biosciences, Inc. (MBX) Stock Statistics & Valuation Metrics

MBX Biosciences, Inc. has a market cap or net worth of $1.11B. The enterprise value is ―.

MBX Biosciences, Inc. has 44,715,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

MBX Biosciences, Inc.’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -26.45%.

The current PE Ratio of MBX Biosciences, Inc. is ―. MBX Biosciences, Inc.’s PEG ratio is -0.12.

In the last 12 months, MBX Biosciences, Inc. had revenue of 0.00 and earned -61.92M in profits. Earnings per share was -1.85.

In the last 12 months, operating cash flow was -77.69M and capital expenditures -1.23M, giving a free cash flow of -78.91M billion.

MBX Biosciences, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

MBX Biosciences, Inc. upcoming earnings date is Mar 23, 2026, Before Open (Confirmed).

MBX Biosciences, Inc. as a current ratio of 24.19, with Debt / Equity ratio of 0.16%

In the past 12 months, MBX Biosciences, Inc. has paid 0.00 in taxes.

MBX Biosciences, Inc. EV to EBITDA ratio is -8.33, with an EV/FCF ratio of -10.19.

MBX Biosciences, Inc. has $391.67M in cash and marketable securities with $623.00K in debt, giving a net cash position of $391.05M billion.

Gross margin is -29.73%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for MBX Biosciences, Inc. is $64.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy